These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35862725)

  • 1. Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis.
    Saha A; Roy S; Ukil A
    Infect Immun; 2022 Aug; 90(8):e0024822. PubMed ID: 35862725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Treg, Breg and other cytokine sets in host protection and immunopathology during human leishmaniasis: Are they potential valuable markers in clinical settings and vaccine evaluation?
    Divenuto F; Pavia G; Marascio N; Barreca GS; Quirino A; Matera G
    Acta Trop; 2023 Apr; 240():106849. PubMed ID: 36731621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
    Gravino AE
    Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Leishmania-macrophage interactions: role of cytokines and molecules co-involved in killing].
    Faliero SM; Marzio R; Panaro MA; Brandonisio O
    Parassitologia; 1995 Apr; 37(1):5-15. PubMed ID: 8532367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulator and effector functions of T-cell subsets in human Leishmania infections.
    Kemp M
    APMIS Suppl; 1997; 68():1-33. PubMed ID: 9063493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central and local controls of monocytopoiesis influence the outcome of Leishmania infection.
    Raybarman C; Bhattacharjee S
    Cytokine; 2021 Nov; 147():155325. PubMed ID: 33039254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review on the Role of Host Immune Response in Protection and Immunopathogenesis during Cutaneous Leishmaniasis Infection.
    Dubie T; Mohammed Y
    J Immunol Res; 2020; 2020():2496713. PubMed ID: 32656269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.
    Soong L; Henard CA; Melby PC
    Semin Immunopathol; 2012 Nov; 34(6):735-51. PubMed ID: 23053396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cure of progressive murine leishmaniasis: interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell type 1-selective cytokine therapy.
    Heinzel FP; Rerko RM
    J Exp Med; 1999 Jun; 189(12):1895-906. PubMed ID: 10377185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
    Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
    Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
    Rostan O; Gangneux JP; Piquet-Pellorce C; Manuel C; McKenzie AN; Guiguen C; Samson M; Robert-Gangneux F
    mBio; 2013 Sep; 4(5):e00383-13. PubMed ID: 24045639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunopathology of American tegumentary leishmaniasis].
    Castés M; Tapia FJ
    Acta Cient Venez; 1998; 49(1):42-56. PubMed ID: 10205916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-producing T cell subsets in human leishmaniasis.
    Kemp K
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):173-6. PubMed ID: 10912621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine saga in visceral leishmaniasis.
    Bhor R; Rafati S; Pai K
    Cytokine; 2021 Nov; 147():155322. PubMed ID: 33127259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis.
    Reiner SL; Locksley RM
    J Cell Biochem; 1993 Dec; 53(4):323-8. PubMed ID: 7905485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopathogenesis of infection with the visceralizing Leishmania species.
    Wilson ME; Jeronimo SM; Pearson RD
    Microb Pathog; 2005 Apr; 38(4):147-60. PubMed ID: 15797810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function.
    Locksley RM; Scott P
    Immunol Today; 1991 Mar; 12(3):A58-61. PubMed ID: 1829891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Th1/Th2 regulatory switch to promote healing response during leishmaniasis: a computational approach.
    Ganguli P; Chowdhury S; Chowdhury S; Sarkar RR
    EURASIP J Bioinform Syst Biol; 2015 Dec; 2015(1):13. PubMed ID: 26660865
    [No Abstract]   [Full Text] [Related]  

  • 19. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
    Bottrel RL; Dutra WO; Martins FA; Gontijo B; Carvalho E; Barral-Netto M; Barral A; Almeida RP; Mayrink W; Locksley R; Gollob KJ
    Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling the unsolved paradoxes of cytokine families in host resistance and susceptibility to
    Osero BO; Aruleba RT; Brombacher F; Hurdayal R
    Cytokine X; 2020 Dec; 2(4):100043. PubMed ID: 33415318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.